Transcriptional Repression of the E2-containing Promoters EIIaE, C-myc, and RB1 by the Product of the RB1 Gene
Overview
Authors
Affiliations
The protein product of the retinoblastoma susceptibility gene, p110RB1, is a nuclear phosphoprotein [W.H. Lee, J.Y. Shew, F.D. Hong, T.W. Sery, L.A. Donoso, L.J. Young, R. Bookstein, and E.Y. Lee, Nature (London) 329:642-645, 1987] with properties of a cell cycle regulator (K. Buchkovich, L.A. Duffy, and E. Harlow, Cell 58:1097-1105, 1989; P.L. Chen, P. Scully, J.Y. Shew, J.Y. Wang, and W.H. Lee, Cell 58:1193-1198, 1989; J.A. DeCaprio, J.W. Ludlow, D. Lynch, Y. Furukawa, J. Griffin, H. Piwnica-Worms, C.M. Huang, and D.M. Livingston, Cell 58:1085-1095, 1989; and K. Mihara, X.R. Cao, A. Yen, S. Chandler, B. Driscoll, A.L. Murphree, A. TAng, and Y.K. Fung, Science 246:1300-1303, 1989). Although the mechanism of action of p110RB1 remains unknown, several lines of evidence suggest that it plays a role in the regulation of transcription. We now show that overexpression of p110RB1 causes repression of the adenovirus early promoter EIIaE and the promoters of two cellular genes, c-myc and RB1, both of which contain E2F-binding motifs. Mutation of the E2 element in the c-myc promoter abolishes p110RB1 repression. We also demonstrate that a p110RB1 mutant, which is refractory to cell cycle phosphorylation but intact in E1a/large T antigen-binding properties, represses EIIaE with 50- to 80-fold greater efficiency than wild-type p110RB1. These data provide evidence that hypophosphorylated p110RB1 actively represses expression of genes with promoters containing the E2F-binding motif (E2 element).
A Drosophila model of HPV16-induced cancer reveals conserved disease mechanism.
Hashemi L, Ormsbee M, Patel P, Nielson J, Ahlander J, Barmchi M PLoS One. 2022; 17(12):e0278058.
PMID: 36508448 PMC: 9744332. DOI: 10.1371/journal.pone.0278058.
Zhang Y, Chen F, Chandrashekar D, Varambally S, Creighton C Nat Commun. 2022; 13(1):2669.
PMID: 35562349 PMC: 9106650. DOI: 10.1038/s41467-022-30342-3.
Pozzoli G, Petrucci G, Navarra P, Marei H, Cenciarelli C J Cell Mol Med. 2019; 23(10):7078-7087.
PMID: 31429199 PMC: 6787451. DOI: 10.1111/jcmm.14610.
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.
Pan Q, Sathe A, Black P, Goebell P, Kamat A, Schmitz-Draeger B Bladder Cancer. 2017; 3(2):79-88.
PMID: 28516152 PMC: 5409046. DOI: 10.3233/BLC-170105.
A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription.
Musahl A, Huang X, Rusakiewicz S, Ntini E, Marsico A, Kroemer G Oncogene. 2015; 34(39):5046-54.
PMID: 25579178 DOI: 10.1038/onc.2014.424.